UNICYCIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 669.50 thousand shares for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-11-12
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 612.40K shares, a 5.09% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was -52.90K shares, a 101.91% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 110.00K shares, a 478.95% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 0.00 shares.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.37M shares, a 62.51% decline from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 8.99M shares, a 2674.53% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 324.00K shares, a 57.38% decline from fiscal 2021.
- UNICYCIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 760.25K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-09-30 | 612.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 559.50K shares derived: sum of 2 quarters · filed 2025-11-12 | 669.50K shares 10-Q · filed 2025-11-12 | 669.50K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | -52.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 57.10K shares 10-Q · filed 2025-08-14 | 57.10K shares derived: sum of 3 quarters · filed 2025-08-14 | 639.81K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 110.00K shares 10-Q · filed 2025-05-14 | 110.00K shares derived: sum of 2 quarters · filed 2025-05-14 | 692.71K shares derived: sum of 3 quarters · filed 2025-05-14 | 3.46M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 582.71K shares derived: sum of 2 quarters · filed 2025-03-31 | 3.35M shares derived: sum of 3 quarters · filed 2025-03-31 | 3.37M shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 582.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 3.35M shares derived: sum of 2 quarters · filed 2024-11-13 | 3.37M shares 10-Q · filed 2024-11-13 | 3.37M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 2.77M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 2.79M shares 10-Q · filed 2024-08-14 | 2.79M shares derived: sum of 3 quarters · filed 2024-08-14 | |
| 2024-03-31 | 19.00K shares 10-Q · filed 2024-05-13 | 19.00K shares derived: sum of 2 quarters · filed 2024-05-13 | ||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 8.99M shares 10-K · filed 2024-03-28 | ||
| 2023-09-30 | 8.99M shares 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | 305.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 310.00K shares derived: sum of 2 quarters · filed 2023-03-31 | 324.00K shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 19.00K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 14.00K shares 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | 440.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 628.15K shares derived: sum of 2 quarters · filed 2022-03-31 | 760.25K shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 187.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 319.75K shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 132.09K shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |